RxDoctor Payments Data

Roxana Llovet, MD

Psychiatry · Bridgeport, CTNPI 1639250087

Payments from drug & device makers

$6,287in general payments, 2019–2025

Across 230 payments — averaging $27.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Lundbeck LLC$874
  • Neurocrine Biosciences, Inc.$792
  • Alkermes, Inc.$777
  • Otsuka America Pharmaceutical, Inc.$286
  • plus $660 from 5 others

What the payments were for

  • Food & beverage$6,01996%
  • Education$2684%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,287 in reported general payments places this provider in the 85th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$23,871
Medicare patients
47
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole68$191,379
Invega SustennaPaliperidone Palmitate38$114,909
IngrezzaValbenazine Tosylate12$92,229
AristadaAripiprazole Lauroxil18$56,237
Wellbutrin XlBupropion Hcl25$54,807
CaplytaLumateperone Tosylate23$36,071
VraylarCariprazine Hcl15$20,289
Risperidone ErRisperidone Microspheres11$19,648
RexultiBrexpiprazole11$17,985
AbilifyAripiprazole12$17,775
Clozapine234$16,729
ProzacFluoxetine Hcl24$14,853
Aripiprazole94$4,815
Haloperidol92$3,560
Focalin XrDexmethylphenidate Hcl12$2,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$286$209,36579 claims
Johnson & JohnsonInvega Sustenna$14$114,90938 claims
Neurocrine Biosciences, Inc.Ingrezza$792$92,22912 claims
Alkermes, Inc.Aristada$777$56,23718 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,361$36,07123 claims
AbbVieVraylar$140$20,28915 claims
E.r. Squibb & Sons, L.L.C.Abilify$273$17,77512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in Bridgeport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →